SEC Form 4 · accession 0000914760-16-000389
ENZO BIOCHEM INC · ENZ
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Bernard L Kasten
Director
Period of report
Jan 6, 2016
Accepted (ET)
Mar 18, 2016 · 2:41 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0000316253
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Jan 21, 2016 | S | 2,500 | $4.656 | D | 40,282 | D | |
| Common Stock | Mar 10, 2016 | S | 1,857 | $4.40 | D | 38,425 | D | |
| Common Stock | Mar 10, 2016 | S | 9,720 | $4.397 | D | 28,705 | D | |
| Common Stock | Mar 10, 2016 | S | 18,651 | $3.466 | D | 10,054 | D | |
| Common Stock | Mar 11, 2016 | S | 3,100 | $4.386 | D | 6,954 | D | |
| Common Stock | Mar 11, 2016 | S | 6,954 | $4.411 | D | 0 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (to acquire common stock)F1 | $4.66 | Jan 6, 2016 | A | 63,291 | A | Jan 7, 2017 | Jan 5, 2021 | Common Stock | 63,291 | 257,455 | D |
Explanation of responses
- F1The Reporting Person was granted 63,291 stock options. The options have a five-year term and shall vest in two equal annual tranches, beginning January 7, 2017.